CD274 and cutaneous melanoma: In line with previous evidence, they found a low tumour mutational burden and lower rates of PD-L1 expression in vulvovaginal melanomas compared with cutaneous melanomas, with a corresponding median overall survival of 17.5 months versus 37.9 months in the two groups, respectively, when treated with ICIs.